SCHEMBL7163447

SCHEMBL7163447

O=Cc1ccc(-c2ccc(O)c(Cc3ccccc3)c2)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP3A4 P08684 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ERN1 O75460 2/20 0.44
BCL2 P10415 1/20 0.42
BCL2L1 Q07817 1/20 0.42
SLC7A5 Q01650 1/20 0.42
PAX8 Q06710 1/20 0.39
PTPN1 P18031 1/20 0.39
ALOX5 P09917 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
HSP90AA1 P07900 1/20 0.38
IDO1 P14902 1/20 0.38
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6704971 0.80 MEN1 (0.49) MEN1KMT2ACYP3A4HPGDALOX15
SCHEMBL5156136 0.77 ESR1 (0.52) MEN1KMT2AHSD17B10ERN1KDM4E
SCHEMBL10558399 0.77 MEN1 (0.67) MEN1KMT2ACYP3A4HPGDALOX15
SCHEMBL8992573 0.74 MEN1 (0.62) MEN1KMT2ACYP3A4HPGDALOX15
SCHEMBL29738649 0.74 MEN1 (0.62) MEN1KMT2ACYP3A4HPGDALOX15
SCHEMBL17188186 0.73 ERN1 (0.46) MEN1KMT2AERN1ALOX5
SCHEMBL26681203 0.72 PELI1 (0.45) MEN1KMT2ACYP3A4HPGDHSD17B10
SCHEMBL30687893 0.72 PELI1 (0.45) MEN1KMT2ACYP3A4HPGDHSD17B10
SCHEMBL5663542 0.72 PTPN1 (0.47) BCL2BCL2L1PTPN1
SCHEMBL4864427 0.72 MEN1 (0.44) MEN1KMT2AHPGDPTPN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6563008-B2 Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast AVENTIS PHARMA S.A. (FR) 2003-05-13 US disclosed